// App-Quantinova.ai

5007 : TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Scott T. Tagawa

Principal Investigators

  • Emmanuel S. Antonarakis

  • Fred Saad

  • Marie Vanhuyse

  • Guru Sonpavde

  • Scott A. North

  • Costantine Albany

  • Che-Kai Tsao

  • John Stewart

  • Atef Zaher

  • Ted P. Szatrowski

  • Wei Zhou

  • Giuseppe Galletti

  • Daniel Worroll

  • Mario A. Eisenberger

  • David M. Nanus

  • Paraskevi Giannakakou

Medical Centers

  • Weill Cornell Medicine, New York, NY

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • University of Montreal Hospital Center, Montreal, QC, Canada

  • Medical Oncology, Montreal General Hospital, Montreal, QC, Canada

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Indiana University School of Medicine, Indianapolis, IN

  • Mount Sinai Medical Center, New York, NY

  • Sanofi, Laval, QC, Canada

  • Sanofi, Bridgewater, NJ

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Cabazitaxel

  • Docetaxel

  • Androgen Tear

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01718353

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved